Panacea Biotec is currently trading at Rs. 157.55, up by 23.55 points or 17.57% from its previous closing of Rs. 134.00 on the BSE.
The scrip opened at Rs. 155.00 and has touched a high and low of Rs. 160.80 and Rs. 152.25 respectively. So far 114471 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 286.00 on 13-Oct-2021 and a 52 week low of Rs. 121.35 on 06-Jul-2022.
Last one week high and low of the scrip stood at Rs. 160.80 and Rs. 130.55 respectively. The current market cap of the company is Rs. 820.76 crore.
The promoters holding in the company stood at 73.59%, while Non-Institutions held 26.41% stake in the company.
Panacea Biotec has received long-term supply awards worth $127.30 million (around Rs 1,040 crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).
UNICEF award is worth $98.755 million (Rs 813 crore) for supply of 99.70 million doses during calendar years 2023-2027 and PAHO award is worth $28.55 million (Rs 235 crore) for supply 24.83 million doses during calendar years 2023-2025.
Panacea Biotec Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases: Diphtheria,
Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.
Easyfive-TT is the world’s first fully liquid wP-based Pentavalent vaccine that as launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally. EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders.
As per Human Vaccines and lmmunotherapeutics, the fully-liquid Pentavalent vaccine has been hailed as a ‘breakthrough in India’s Universal Immunisation Program’ with having averted more than 7 million cases, averted 31,000 deaths, and total benefits exceeding $1 billion in DALY savings in India.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.